Avid Bioservices Inc (CDMO)

[tarvacin]

Astra is paying and probably with milestones

That's not how the PR read.

Read the last 4 AZN cancer deals.


Peregrine Pharmaceuticals, Inc. (PPHM)

Under the terms of the agreement, the initial trial will be conducted by Peregrine.

http://finance.yahoo.com/news/astrazeneca-peregrine-pharmaceuticals-collaborate-immuno-060500667.html


Inovio Pharmaceuticals, Inc. (INO)

AstraZeneca will make an upfront payment of $27.5 million and potential milestones payments totaling up to $700 million
Under the terms of the agreement, Heptares will grant AstraZeneca an exclusive license to research, develop, manufacture and commercialise HTL-1071. The companies will also collaborate to discover further A2A receptor-blocking compounds for development in cancer immunotherapy.

http://finance.yahoo.com/news/inovio-q2-loss-wider-expected-134001157.html


Heptares Therapeutics

Heptares will receive an upfront payment of $10 million and is eligible to receive additional, significant near term milestone payments based on agreed pre-clinical and/or clinical events. Subject to successful completion of development and commercialisation milestones, Heptares is also eligible to receive more than $500 million, as well as up to double-digit tiered royalties on net sales.

http://www.heptares.com/news/242/74/Heptares-and-AstraZeneca-Enter-Agreement-to-Develop-Novel-Immuno-Oncology-Treatments-for-a-Range-of-Cancers.html


Mirati Therapeutics, Inc. (MRTX)

Under the terms of the agreement, Mirati will conduct and fund the initial Phase I/II clinical trial, which is expected to start in 2016, and MedImmune will supply durvalumab for the trial. The parties have established a Joint Steering Committee to oversee the trial. In the event that the initial clinical trial demonstrates positive results, MedImmune will have an exclusive period of time in which to negotiate a commercial license for the combination in this indication.

http://finance.yahoo.com/news/mirati-therapeutics-medimmune-partner-immuno-110000180.html